RWIBX | USCGX | RWIBX / USCGX | |
Total Expense Ratio | 1.51 | 1.13 | 134% |
Annual Report Gross Expense Ratio | 1.51 | 1.13 | 134% |
Fund Existence | 23 years | 25 years | - |
Gain YTD | 8.647 | 7.564 | 114% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 3000 | 8% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 132B | 969M | 13,622% |
Annual Yield % from dividends | 0.86 | 1.77 | 49% |
Returns for 1 year | 5.45 | 0.81 | 675% |
Returns for 3 years | 41.17 | 33.74 | 122% |
Returns for 5 years | 47.82 | 45.63 | 105% |
Returns for 10 years | 47.79 | 44.22 | 108% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FXP | 10.89 | 0.28 | +2.64% |
ProShares UltraShort FTSE China 50 | |||
CLSE | 22.82 | -0.08 | -0.34% |
Convergence Long/Short Equity ETF | |||
BME | 36.21 | -0.22 | -0.60% |
Blackrock Health Sciences Trust | |||
IPAC | 67.86 | -0.58 | -0.85% |
iShares Core MSCI Pacific ETF | |||
SPVM | 57.45 | -0.81 | -1.40% |
Invesco S&P 500 Value with Momentum ETF |